#USA #New York #Rosen Law Firm #Soleno Therapeutics #SLNO

Rosen Law Firm's Class Action Investigation into Soleno Therapeutics

On September 24, 2025, the Rosen Law Firm, renowned for its focus on investor rights, announced an ongoing investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry has been prompted by suspicions that Soleno may have disseminated materially misleading business information to its shareholders. This investigation seeks to determine if any legal action is warranted for potential securities violations that could allow affected investors to seek compensation without incurring out-of-pocket expenses.

Background of the Investigation

The impetus for the investigation dates back to August 15, 2025, when a significant decline in Soleno Therapeutics' stock was reported following a critical short report by Scorpion Capital. This report raised alarm over the company's recently approved drug for Prader-Willi syndrome, known as VYKAT XR. Concerns highlighted included serious safety issues, which led to fears that the drug might be withdrawn from the market or could experience a severe drop in prescription rates.

As a direct consequence of this troubling news, Soleno's stock plummeted by 7.4% on the same day. This downward trajectory continued the following trading day, where the stock dropped an additional 4.9%. Such alarming declines in stock performance have prompted the Rosen Law Firm to take action, encouraging shareholders who believe they have suffered losses to step forward.

Joining the Class Action

For investors of Soleno Therapeutics, this is a critical moment. Anyone who purchased Soleno stock may be entitled to recovery through a class action lawsuit spearheaded by the Rosen Law Firm. Interested parties can join this prospective class action easily by accessing this link or by calling Phillip Kim, Esq., toll-free at 866-767-3653. Direct inquiries can also be made via email at [email protected].

The Importance of Experienced Legal Counsel

The Rosen Law Firm emphasizes the significance of selecting experienced legal counsel. Their firm has a storied history and is distinguished for its dedication to securities class actions and shareholder derivative litigation. In the realm of securities litigation, the Rosen Law Firm achieved a remarkable milestone by securing the largest settlement ever against a Chinese company and has consistently ranked among the top firms in securities class action settlements for a decade.

They remind investors to exercise caution when choosing legal representation, noting that not all law firms possess the necessary expertise or resources to effectively undertake class actions. Since 2013, the Rosen Law Firm has recovered hundreds of millions for investors, and in a standout year like 2019, they secured over $438 million in settlements.

Stay Informed

Investors and interested parties are encouraged to stay updated on this developing situation. The Rosen Law Firm provides ongoing information via their LinkedIn, Twitter, and Facebook platforms, ensuring that investors are apprised of any significant developments regarding the class action and their rights as shareholders.

In summary, while the stock market downturn for Soleno Therapeutics has raised red flags for investors, the Rosen Law Firm is taking the initiative to ensure that affected shareholders have an avenue for recourse should the allegations against the company be substantiated. The firm invites anyone who has faced losses due to Soleno Therapeutics' actions to reach out and explore their options for compensation.